Nutrien Q1 Potash Volumes Hit Record, Adjusted EPS In Line

What happened

Nutrien reported Q1 2026 adjusted EBITDA of $1.11B and adjusted EPS of $0.51, with record potash sales volumes and stronger Nitrogen and Retail segments. Net earnings of $139M ($0.27 diluted) were depressed by one-time items, but the operational core performed well. The record potash volumes support management's 2026 guidance of 14.1-14.8 Mt, a key pillar of the investment thesis. However, adjusted EPS of $0.51, while solid, is not a game-changer given the stock's 41% YTD rise from $50 to $72. The quarter reinforces the base case but provides no new catalyst for the bull case, which depends on a phosphate strategic alternative.

Implication

For investors, Q1 results validate Nutrien's potash volume narrative and keep the base-case valuation of $80 in play. The record potash volumes demonstrate tight market conditions and Nutrien's logistics capability. However, the stock price already embeds much of this operational success, and the lack of phosphate strategic progress means the next leg up depends on either potash price strength or a concrete deal. Monitor future quarters for volume persistence and phosphate milestones. The attractive entry remains near $66, and trim above $85 as previously outlined.

Thesis delta

The Q1 results confirm the potash volume thesis but do not accelerate the phosphate catalyst timeline. The stock's 41% run has compressed the margin of safety, making further gains reliant on either higher potash prices or a phosphate transaction. The base case remains intact, but the risk/reward is more balanced now; no change to the POTENTIAL BUY rating but confidence is moderate.